Skip to main content
. 2022 Aug 22;7(5):100558. doi: 10.1016/j.esmoop.2022.100558

Figure 2.

Figure 2

Figure 2

Progression-free survival curves comparing PARPi versus placebo in subgroups: combined individual patient data from four RCTs. (A) Germline and/or tumor BRCA mutated. (B) HRD positive including BRCA mutated. (C) HRD positive excluding BRCA mutated. (D) HRD negative.CI, confidence interval; HR, hazard ratio; HRD, homologous recombination deficiency; PARPi, poly(ADP-ribose) polymerase inhibitor; PFS, progression-free survival; RCT, randomized controlled trial.